Erken Evre Kronik Lenfositik Lösemide Tiroid Antikorları ve İnsülin Direnci Sıklığının Araştırılması

Amaç: Kronik lenfositik lösemi dünyada erişkinlerde görülen en yaygın lösemi tipidir. Hashimoto tiroiditi, otoimmün tiroid hastalığının en yaygın şeklidir. Genellikle yüksek seviyelerde tiroglobulin antikorları veya tiroid peroksidaz antikorları bulunur. Metabolik sendrom da dünyada çok yaygın görülmektedir ve dünyayı tehdit eden bir halk sağlığı sorunu haline gelmiştir. Metabolik sendrom, kronik lenfositik lösemi ve otoimmün tiroid hastalıklarındaki immün disregülasyon bu hastalıkları ortak paydada birleştirmektedir. Bu ortak mekanizmaya dayanarak çalışmamızda erken evre kronik lenfositik lösemili hastalarda insülin direnci ve tiroid otoantikorlarının sıklığını araştırmayı amaçladık. Gereç ve Yöntem: Çalışmaya 65 erken evre kronik lenfositik lösemi hastası, 68 sağlıklı kontrol grubu dahil edildi. Hastalarda ve kontrol grubunda tiroid stimülan hormon, tiroglobulin antikorları, tiroid peroksidaz antikorları, açlık kan şekeri, açlık insülin düzeyleri ölçüldü. İstatistiksel değerlendirme Statistical Package for Social Sciences (SPSS) for Windows 20 (IBM SPSS Inc., Chicago, IL) programı kullanılarak yapıldı. Verilerin normal dağılımı Kolmogorov-Smirnov testi ile değerlendirildi. Normal dağılım gösteren sayısal değişkenler ortalama ± standart sapma olarak, normal dağılım göstermeyen sayısal değişkenler ortanca (minimum, maksimum) olarak gösterildi. İstatistiksel analizlerde p0,05). Sonuç: Erken evre kronik lenfositik lösemide insülin direnci ve tiroid antikorları sıklığının sağlıklı kontrollerden farklı olmadığı görüldü.

Investigation of The Frequency of Thyroid Antibodies and Insulin Resistance in Early Stage Chronic Lymphocytic Leukemia

Objectives: Chronic lymphocytic leukemia is the most common type of leukemia seen in adults worldwide. Hashimoto’s thyroiditis is the most common form of autoimmune thyroid disease. Usually, there are high levels of thyroglobulin antibodies or thyroid peroxidase antibodies. Metabolic syndrome is also very common in the world and has become a public health problem threatening the world. Immune dysregulation in metabolic syndrome, chronic lymphocytic leukemia, and autoimmune thyroid diseases unites these diseases on a common denominator. Based on this common mechanism, we aimed to investigate the frequency of insulin resistance and thyroid autoantibodies in patients with early-stage chronic lymphocytic leukemia. Materials and Methods: Sixty-five early-stage chronic lymphocytic leukemia patients and 68 healthy controls were included in the study. Thyroid stimulating hormone, thyroglobulin antibodies, thyroid peroxidase antibodies, fasting blood glucose and fasting insulin levels were measured in the patients and control groups. Statistical evaluation was performed using the Statistical Package for Social Sciences (SPSS) for Windows 20 (IBM SPSS Inc., Chicago, IL) program. The normal distribution of the data was evaluated with the Kolmogorov-Smirnov test. Normally distributed numerical variables were shown as mean ± standard deviation, while numerical variables not showing normal distribution were shown as median (minimum, maximum). P0.05). Conclusion: It was observed that the frequency of insulin resistance and thyroid antibodies in early-stage chronic lymphocytic leukemia was not different from healthy controls.

PDF

___

1. Redaelli A, Laskin BL, Stephens JM, et al. The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care (Engl). 2004;13:279-287.
2. Kipps TJ, Stevenson FK, Wu CJ, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017;3:16096.
3. Riches JC, Ramsay AG, Gribben JG. T-cell function in chronic lymphocytic leukaemia. Semin Cancer Biol. 2010;20:431-438.
4. Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005;106:2018-2025.
5. Giannopoulos K, Schmitt M, Kowal M, et al. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep. 2008;20:677-682.
6. Jadidi-Niaragh F, Ghalamfarsa G, Yousefi M, et al. Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions. Tumour Biol. 2013;34:2031-2039.
7. Lad DP, Varma S, Varma N, et al. Regulatory T-cell and T-helper 17 balance in chronic lymphocytic leukemia progression and autoimmune cytopenias. Leuk Lymphoma. 2015;56:2424-2428.
8. Mao C, Wang S, Xiao Y, et al. Impairment of regulatory capacity of CD4+CD25+ regulatory T cells mediated by dendritic cell polarization and hyperthyroidism in Graves’ disease. J Immunol. 2011;186:4734-4743.
9. Glick AB, Wodzinski A, Fu P, et al. Impairment of regulatory T-cell function in autoimmune thyroid disease. Thyroid. 2013;23:871-878.
10. Raposo L, Martins S, Ferreira D, et al. Metabolic Syndrome, Thyroid Function and Autoimmunity - The PORMETS Study. Endocr Metab Immune Disord Drug Targets. 2019;19:75-83.
11. Liu Y, Tang X, Tian J, et al. Th17/Treg cells imbalance and GITRL profile in patients with Hashimoto’s thyroiditis. Int J Mol Sci. 2014;15:21674-21686.
12. Li C, Yuan J, Zhu YF, et al. Imbalance of Th17/Treg in Different Subtypes of Autoimmune Thyroid Diseases. Cell Physiol Biochem. 2016;40:245-252.
13. Chen WH, Chen YK, Lin CL, et al. Hashimoto’s thyroiditis, risk of coronary heart disease, and L-thyroxine treatment: a nationwide cohort study. J Clin Endocrinol Metab. 2015;100:109-114.
14. He M, Zhang W, Dong Y, et al. Pro-inflammation NF-κB signaling triggers a positive feedback via enhancing cholesterol accumulation in liver cancer cells. J Exp Clin Cancer Res. 2017;36:15.
15. Kassi E, Pervanidou P, Kaltsas G, et al. Metabolic syndrome: definitions and controversies. BMC Med. 2011;9:48.
16. Zhou H, Liu F. Regulation, Communication, and Functional Roles of Adipose Tissue-Resident CD4+ T Cells in the Control of Metabolic Homeostasis. Front Immunol. 2018;9:1961.
17. Kato I, Tajima K, Suchi T, et al. Chronic thyroiditis as a risk factor of B-cell lymphoma in the thyroid gland. Jpn J Cancer Res. 1985;76:1085-1090.
18. Holm LE, Blomgren H, Löwhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med. 1985;312:601-604.
19. Tao L, Liu H, Gong Y. Role and mechanism of the Th17/Treg cell balance in the development and progression of insulin resistance. Mol Cell Biochem. 2019;459:183-188.
20. Dimitriadis G, Baker B, Marsh H, et al. Effect of thyroid hormone excess on action, secretion, and metabolism of insulin in humans. Am J Physiol. 1985;248:593-601.
21. Dimitriadis G, Mitrou P, Lambadiari V, et al. Insulin action in adipose tissue and muscle in hypothyroidism. J Clin Endocrinol Metab. 2006;91:4930- 4937.
22. Liu J, Duan Y, Fu J et al. Association between thyroid hormones, thyroid antibodies, and cardiometabolic factors in non-obese individuals with normal thyroid function. Front Endocrinol (Lausanne) 2018;9:130.
23. Fabbrini E, Cella M, McCartney SA, et al Association between specific adipose tissue CD4+ T-cell populations and insulin resistance in obese individuals. Gastroenterology. 2013;145:366-374.
24. O’Rourke RW, Lumeng CN. Obesity heats up adipose tissue lymphocytes. Gastroenterology. 2013;145:282-285.
25. Chuang HC, Sheu WH, Lin YT, et al. HGK/MAP4K4 deficiency induces TRAF2 stabilization and Th17 differentiation leading to insulin resistance. Nat Commun. 2014;5:4602.
26. Vitales-Noyola M, Ramos-Levi AM, Martínez-Hernández R, et al. Pathogenic Th17 and Th22 cells are increased in patients with autoimmune thyroid disorders. Endocrine. 2017;57:409-417.
27. Giordano C, Stassi G, De Maria R, et al. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto’s thyroiditis. Science. 1997;275:960-963.
28. Beyan C, Kaptan K, Ifran A. Coexistence of chronic lymphocytic leukemia and Hashimoto’s thyroiditis. Ann Hematol. 2006;85:811-812.
29. Zhou YP, Pena JC, Roe MW, et al. Overexpression of Bcl-x(L) in beta-cells prevents cell death but impairs mitochondrial signal for insulin secretion. Am J Physiol Endocrinol Metab. 2000;278:340-351.
30. Luciani DS, White SA, Widenmaier SB, et al. Bcl-2 and Bcl-xL suppress glucose signaling in pancreatic β-cells. Diabetes. 2013;62:170-182.
31. Ougolkov AV, Bone ND, Fernandez-Zapico ME, et al. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood. 2007;110:735-742.
32. Larsson SC, Wolk A. Overweight and obesity and incidence of leukemia: a meta-analysis of cohort studies. Int J Cancer. 2008;122:1418-1421.
33. Pothiwala P, Jain SK, Yaturu S. Metabolic syndrome and cancer. Metab Syndr Relat Disord. 2009;7:279-288.
34. Cowey S, Hardy RW. The metabolic syndrome: A high-risk state for cancer? Am J Pathol. 2006;169:1505-1522.
35. Henriksen EJ, Dokken BB. Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Curr Drug Targets. 2006;7:1435-1441.
36. Rebolleda N, Losada-Fernandez I, Perez-Chacon G, et al. Synergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine Model. PLoS One. 2016;11:0154159.
37. Kulikov R, Boehme KA, Blattner C. Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance. Mol Cell Biol. 2005;25:7170-7180.